EXITS

Investing in companies and technologies that address unmet health and economic needs
AorTx, Inc.

Redwood City, CA

BioStar I

AorTx, Inc. was formed to develop an aortic valve that could be delivered both transapically and percutaneously. AorTx, Inc. was acquired by Hansen Medical, Inc. (NASDAQ:HNSN).

 
 
Atritech, Inc.

Plymouth, MN

BioStar I

Atritech, Inc. developed the WATCHMAN, a proprietary minimally invasive device designed to prevent thrombi (blood clots) that form in the left atrial appendage of the heart during an atrial fibrillation event. Atritech, Inc. was acquired by Boston Scientific Corporation (NYSE:BSX).

CD Diagnostics, Inc.

Claymont, DE

BioStar II

CD Diagnostics, Inc. became a fully integrated diagnostics company focused on developing immunoassays that improve patient outcomes. The company developed a novel biomarker detection technology for rapid diagnosis of periprosthetic joint infection and was acquired by Zimmer Biomet (NYSE:ZBH) in 2016.

 
 
CV Ingenuity Corp.

Palo Alto, CA

BioStar II

CV Ingenuity Corp., located in Palo Alto, CA, was a leading drug-eluting balloon technology company and was acquired by Covidien (NYSE:COV).

 
Ellipse Technologies, Inc.

Aliso Viejo, CA

BioStar II

Ellipse Technologies, Inc., located in Irvine, CA, developed a non-invasively adjustable magnetic implant platform used to treat a broad spectrum of spinal, orthopedic, and deformity conditions, including limb length discrepancies and scoliosis. The company was acquired by NuVasive, Inc. (NASDAQ:NUVA) in 2016.

 
Embrella Cardiovascular, Inc.

Wayne, PA

BioStar I, BioStar II

Embrella Cardiovascular, Inc. was established to create a new standard-of-care for embolic cerebral protection during cardiovascular procedures. Embrella Cardiovascular, Inc. was acquired by Edwards Lifesciences Corp. (NYSE:EW).

 
Hotspur Technologies, Inc.

Mountain View, CA

BioStar II

Hotspur Technologies, Inc., located in Mountain View, CA, develops, manufactures, and sells a number of innovative balloon catheter systems for the dialysis access and peripheral arterial disease markets. Hotspur Technologies was acquired by Teleflex Incorporated (NYSE:TFX).

 
Nellix Endovascular, Inc.

Palo Alto, CA

BioStar I

Nellix Endovascular, Inc. has developed a revolutionary device for the less invasive treatment of Abdominal Aortic Aneurysms (AAA) and Thoracic Aortic Aneurysms (TAA). Nellix Endovascular, Inc. was acquired by Endologix, Inc. (NASDAQ:ELGX).

Ortho-Space Ltd.

Caesarea, Israel

BioStar II

Ortho-Space Ltd., located in Caesarea, Israel, developed an implantable, biodegradable balloon that is deployed in a minimally invasive, outpatient procedure and returns range of motion while relieving pain in patients with massive tears of the rotator cuff.

www.orthospace.co.il

 
 
ReVascular Therapeutics, Inc.

Sunnyvale, CA

BioStar I

ReVascular Therapeutics, Inc. has pioneered advances in the intravascular treatment of complex lesions and Chronic Total Occlusions (CTOs). The company was purchased by Boston Scientific Corporation (NYSE:BSX).

 
Reverse Medical Corporation

Irvine, CA

BioStar II

Reverse Medical Corporation, located in Irvine, CA, has developed a suite of state-of-the-art endovascular treatments for a broad spectrum of neurovascular disorders and carotid artery disease. In January 2012, the company sold a line of neurovascular guide catheters to Covidien (NYSE:COV) and distributed a dividend to its investors. Reverse Medical Corporation was acquired in its entirety by Covidien (NYSE:COV) in August 2014.

 
Setagon, Inc.

Charlottesville, VA

BioStar I

Setagon, Inc. was developing a next-generation drug delivery system for the emerging market of drug-coated stents. Setagon, Inc. was acquired by Medtronic (NYSE:MDT).